Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics
New York, USA, July 16, 2025 (GLOBE NEWSWIRE) — Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics | DelveInsight
The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT), AI-powered applications, and smart wearables are transforming the diagnostic landscape by making it more accessible and user-friendly. These innovations not only reduce the dependency on traditional sleep labs but also facilitate earlier diagnosis and timely intervention. As a result, more patients are entering the treatment pathway, supporting both improved clinical outcomes and sustained market expansion.
DelveInsight's 'Obstructive Sleep Apnea Pipeline Insight 2025' report provides comprehensive global coverage of pipeline obstructive sleep apnea therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obstructive sleep apnea pipeline domain.
Key Takeaways from the Obstructive Sleep Apnea Pipeline Report DelveInsight's obstructive sleep apnea pipeline report depicts a robust space with 12+ active players working to develop 14+ pipeline obstructive sleep apnea drugs.
active players working to develop pipeline obstructive sleep apnea drugs. Key obstructive sleep apnea companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science , and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape.
and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape. Promising pipeline obstructive sleep apnea therapies, such as Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others, are in different phases of obstructive sleep apnea clinical trials.
and others, are in different phases of obstructive sleep apnea clinical trials. In June 2025 , Innovent Biologics, Inc. announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of Mazdutide , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2).
, announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with and obesity (BMI ≥ 28 kg/m2). In April 202 5, Apnimed announced that the first patient had been dosed in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, SASS-001 , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi).
5, announced that the in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi). In April 2025 , Shionogi & Co., Ltd. announced that it had entered into an agreement with Apnimed, Inc. for the introduction of sulthiame * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed.
, Shionogi & Co., Ltd. announced that it had entered into an with for the introduction of * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed. In April 2025 , Apnimed announced that it had acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame , a differentiated carbonic anhydrase inhibitor, in the broad field of sleep apnea and sleep-related breathing diseases, from D esitin Arzneimittel GmbH . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS).
, announced that it had to develop and commercialize , a differentiated carbonic anhydrase inhibitor, in the broad field of and sleep-related breathing diseases, from D . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS). In April 2025 , Incannex Healthcare Inc. announced that the Company has completed Phase II patient enrollment in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.
, announced that the Company has in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality. In January 2025, Mineralys Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had cleared the Company's Investigational New Drug (IND) Application for a Phase II clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.
Request a sample and discover the recent advances in obstructive sleep apnea drugs @ Obstructive Sleep Apnea Pipeline Report
The obstructive sleep apnea pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Obstructive Sleep Apnea drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obstructive sleep apnea clinical trial landscape.
Obstructive Sleep Apnea Overview
Obstructive sleep apnea (OSA) is a sleep disorder marked by repeated episodes of partial or complete blockage of the upper airway during sleep. These episodes cause drops in oxygen levels and frequent awakenings, resulting in fragmented, poor-quality sleep. Common signs include loud snoring, witnessed pauses in breathing, and excessive daytime sleepiness. OSA can have wide-ranging health effects, impairing cardiovascular health, behavior, quality of life, and even driving safety. While other types of sleep-disordered breathing, such as central sleep apnea, upper airway resistance syndrome, and obesity hypoventilation, share some features with OSA, they are distinct conditions and will be discussed separately.
The symptoms of OSA vary and can severely impact day-to-day functioning. These include persistent daytime drowsiness, loud snoring, gasping or choking during sleep, morning headaches, dry mouth or sore throat upon waking, difficulty concentrating, mood disturbances such as irritability or depression, high blood pressure, and reduced libido. These manifestations can greatly affect both physical well-being and overall life quality.
The underlying cause of OSA involves upper airway obstruction during sleep, mainly due to negative pressure that causes the airway to collapse during inhalation. A key area of concern is the narrowing of the airway in the retropalatal region during exhalation. Obesity is a significant risk factor, with a higher body mass index (BMI) linked to greater airway narrowing. Both structural factors (like airway size) and neuromuscular control contribute to this condition. Understanding how airflow interacts with pressure in collapsible airways is vital to grasping the mechanics of OSA. Additional anatomical and physiological factors also influence the severity of the disorder.
Managing OSA requires a personalized and multifaceted approach. For mild-to-moderate cases, lifestyle changes, such as losing weight, maintaining good sleep habits, and avoiding alcohol and sedatives, are important first steps. Continuous positive airway pressure (CPAP) therapy is the most effective treatment for moderate-to-severe OSA, though adherence can be difficult. Alternatives like oral appliances, especially mandibular advancement devices, may help in less severe cases. Surgical options, including uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (HNS), may be considered for more severe or treatment-resistant cases. In rare, severe situations, a tracheostomy may be necessary, particularly for patients with significant comorbidities. Ultimately, the best outcomes are achieved through an individualized treatment plan that may combine several strategies to relieve symptoms, improve sleep quality, and enhance overall health.
Find out more about obstructive sleep apnea drugs @ Obstructive Sleep Apnea Treatment
A snapshot of the Pipeline Obstructive Sleep Apnea Drugs mentioned in the report: Drugs Company Phase MoA RoA AD109 Apnimed III Adrenergic uptake inhibitors; Cholinergic receptor antagonists; Muscarinic receptor antagonists Oral Retatrutide Eli Lilly and Company III Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists Subcutaneous IHL-42X Incannex Healthcare Ltd II/III Cannabinoid receptor CB2 agonists; Carbonic anhydrase inhibitors Oral Lorundrostat Mineralys Therapeutics Inc. II Aldosterone synthase inhibitors Oral Sulthiame Apnimed II Carbonic anhydrase inhibitors Oral SASS-001 Shionogi Apnimed Sleep Science II Purinergic P2X3 receptor antagonists Oral
Learn more about the emerging obstructive sleep apnea therapies @ Obstructive Sleep Apnea Clinical Trials
Obstructive Sleep Apnea Therapeutics Assessment
The obstructive sleep apnea pipeline report proffers an integral view of the emerging obstructive sleep apnea therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Obstructive Sleep Apnea Pipeline Report Coverage : Global
: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists
: Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists Key Obstructive Sleep Apnea Companies : Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others.
: Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others. Key Obstructive Sleep Apnea Pipeline Therapies: Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others.
Dive deep into rich insights for new obstructive sleep apnea treatments, visit @ Obstructive Sleep Apnea Drugs
Table of Contents 1. Obstructive Sleep Apnea Pipeline Report Introduction 2. Obstructive Sleep Apnea Pipeline Report Executive Summary 3. Obstructive Sleep Apnea Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Obstructive Sleep Apnea Clinical Trial Therapeutics 6. Obstructive Sleep Apnea Pipeline: Late-Stage Products (Pre-registration) 7. Obstructive Sleep Apnea Pipeline: Late-Stage Products (Phase III) 8. Obstructive Sleep Apnea Pipeline: Mid-Stage Products (Phase II) 9. Obstructive Sleep Apnea Pipeline: Early-Stage Products (Phase I) 10. Obstructive Sleep Apnea Pipeline Therapeutics Assessment 11. Inactive Products in the Obstructive Sleep Apnea Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Obstructive Sleep Apnea Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix
For further information on the obstructive sleep apnea pipeline therapeutics, reach out @ Obstructive Sleep Apnea Therapeutics
Related Reports
Obstructive Sleep Apnea Epidemiology Forecast
Obstructive Sleep Apnea Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted obstructive sleep apnea epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Obstructive Sleep Apnea Market
Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., among others.
Sleep Apnea Market
Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others.
Sleep Apnea Pipeline
Sleep Apnea Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others.
Sleep Apnea Diagnostic Devices Market
Sleep Apnea Diagnostic Devices Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea diagnostic devices companies, including Natus Medical Incorporated., SOMNOmedics GmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited., ActiGraph, LLC., Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A., among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
2 hours ago
- Scientific American
Organs Age in Waves Accelerating at 50 Years Old
It is a warning that middle-aged people have long offered the young: ageing is not a smooth process. Now, an exhaustive analysis of how proteins change over time in different organs backs up that idea, finding that people experience an inflection point at around 50 years old, after which ageing seems to accelerate. The study, published 25 July in Cell, also suggests that some tissues — especially blood vessels — age faster than others, and it identifies molecules that can hasten the march of time. The findings add to mounting evidence that ageing is not linear, but is instead pockmarked by periods of rapid change. Even so, larger studies are needed before scientists can label the age of 50 as a crisis point, says Maja Olecka, who studies ageing at the Leibniz Institute on Aging — Fritz Lipmann Institute in Jena, Germany, and was not involved in the study. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. 'There are these waves of age-related changes,' she says. 'But it is still difficult to make a general conclusion about the timing of the inflection points.' Showing their age Previous work has shown that different organs can age at different rates. To further unpick this, Guanghui Liu, who studies regenerative medicine at the Chinese Academy of Sciences in Beijing, and his colleagues, collected tissue samples from 76 people of Chinese ancestry aged 14 to 68 who had died from accidental brain injury. The samples came from organs representing eight of the body's systems, including the cardiovascular, immune and digestive systems. The researchers then created a compendium of the proteins found in each of the samples. They found age-related increases in the expression of 48 disease-associated proteins, and saw early changes at around age 30 in the adrenal gland, which is responsible for producing various hormones. This tracks well with previous data, says Michael Snyder, a geneticist at the Stanford University School of Medicine in California. 'It fits the idea that your hormonal and metabolic control are a big deal,' he says. 'That is where some of the most profound shifts occur as people age.' Between the ages of 45 and 55 came a turning point marked by large changes in protein levels. The most dramatic shift was found in the aorta, the body's main artery, which carries oxygenated blood out of the heart. The team tracked down one protein produced in the aorta that, when administered to mice, triggers signs of accelerated ageing. Liu speculates that blood vessels act as a conduit, carrying molecules that promote ageing to remote destinations throughout the body. The study is an important addition to others that have analysed molecules circulating in the blood, rather than tissue samples taken from individual organs, as a way to monitor age-related changes, says Snyder. 'We're like a car,' he says. 'Some parts wear out faster.' Knowing which parts are prone to wear and tear can help researchers to develop ways to intervene to promote healthy ageing, he says. Halfway to 100 Last year, Snyder and his colleagues found ageing inflection points around the ages of 44 and 60. Other studies have found accelerated ageing at different times, including at around 80 years old, which was beyond the scope of the current study, says Olecka. Discrepancies with other studies can emerge from their use of different kinds of samples, populations and analytical approaches, says Liu. As data build over time, key molecular pathways involved in ageing will probably converge across studies, he adds. These data will accumulate rapidly, says Olecka, because researchers are increasingly incorporating detailed time series in their studies, rather than simply comparing 'young' with 'old'. And those results could help researchers to interpret these periods of rapid change. 'Currently, we do not understand what triggers this transition point,' she says. 'It's a really intriguing emerging field.'
San Francisco Chronicle
5 hours ago
- San Francisco Chronicle
Southern China hit by outbreak of mosquito-borne infection chikungunya
China is experiencing an outbreak of chikungunya, a mosquito-borne infection, with thousands of cases reported in the south. Chikungunya fever cases jumped to 4,014 on Friday, representing a rapid rise in numbers since authorities started tracking cases two weeks ago, according to public records released by health departments in districts in Foshan. The city in China's southern province Guangdong has been heavily impacted by the surge in infections. The chikungunya outbreak remains 'quite severe,' Sun Yang, deputy director of the National Center for Disease Control and Prevention, said at a news conference on Wednesday in Foshan. Chikungunya is spread to people by the bites of infected mosquitoes. It causes fever and severe joint pain, but deaths are rare, according to the World Health Organization. The Chinese Center for Disease Control and Prevention has issued various advisories on how to prevent chikungunya fever and dengue fever, a similar disease also spread by mosquitoes. Physical protection barriers, such as screen doors, mosquito nets for beds and mosquito repellent on exposed skin, was recommended. It said that the epidemic was 'imported' without specifying from where. The Chinese agency also called for people who have symptoms like fever, rash and joint pain to see a doctor. Shunde district in Foshan, where 90% of the cases are located, is famous for its Cantonese food, and sees many visitors each year. Patients who tested positive for chikungunya fever stayed in hospital beds covered by mosquito nets, according to photos shown on state-run broadcaster CCTV. Local media reports said on Thursday that local authorities had almost doubled the number of mosquito-proof isolation beds to 7,220 to meet the growing demand. Authorities in Guangdong are urging residents to make sure there's no standing water in their homes, such as in flowerpots, coffee machines or spare bottles. The Health Commission in Foshan stated on Thursday that a fine of up to 10,000 yuan ($1,400) could be applied if violations are found. The Beijing CDC said on Tuesday that the city occasionally experiences imported cases of chikungunya fever. There are two chikungunya vaccines that have received regulatory approvals in several countries and/or have been recommended for use in populations at risk, but the vaccines are neither widely available nor in widespread use, according to WHO.
Hamilton Spectator
5 hours ago
- Hamilton Spectator
Southern China hit by outbreak of mosquito-borne infection chikungunya
China is experiencing an outbreak of chikungunya, a mosquito-borne infection, with thousands of cases reported in the south. Chikungunya fever cases jumped to 4,014 on Friday, representing a rapid rise in numbers since authorities started tracking cases two weeks ago, according to public records released by health departments in districts in Foshan. The city in China's southern province Guangdong has been heavily impacted by the surge in infections. The chikungunya outbreak remains 'quite severe,' Sun Yang, deputy director of the National Center for Disease Control and Prevention, said at a news conference on Wednesday in Foshan. Chikungunya is spread to people by the bites of infected mosquitoes. It causes fever and severe joint pain, but deaths are rare, according to the World Health Organization. The Chinese Center for Disease Control and Prevention has issued various advisories on how to prevent chikungunya fever and dengue fever, a similar disease also spread by mosquitoes. Physical protection barriers, such as screen doors, mosquito nets for beds and mosquito repellent on exposed skin, was recommended. It said that the epidemic was 'imported' without specifying from where. The Chinese agency also called for people who have symptoms like fever, rash and joint pain to see a doctor. Shunde district in Foshan, where 90% of the cases are located, is famous for its Cantonese food, and sees many visitors each year. Patients who tested positive for chikungunya fever stayed in hospital beds covered by mosquito nets, according to photos shown on state-run broadcaster CCTV. Local media reports said on Thursday that local authorities had almost doubled the number of mosquito-proof isolation beds to 7,220 to meet the growing demand. Authorities in Guangdong are urging residents to make sure there's no standing water in their homes, such as in flowerpots, coffee machines or spare bottles. The Health Commission in Foshan stated on Thursday that a fine of up to 10,000 yuan ($1,400) could be applied if violations are found. The Beijing CDC said on Tuesday that the city occasionally experiences imported cases of chikungunya fever. There are two chikungunya vaccines that have received regulatory approvals in several countries and/or have been recommended for use in populations at risk, but the vaccines are neither widely available nor in widespread use, according to WHO. China had its first chikungunya spike in 2010 with 253 cases in Dongguan, a nearby city in the same province, according to the Guangdong provincial CDC. Several cases were found in years since then, but they weren't widespread. The country's first case was imported in 1987, according to research papers and media reports.
